By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
By Dr. Lei Deng University of Washington & Fred Hutch Watch Dr. Lei Deng’s overview of the KEYNOTE-671 and NADIM II trials, with important implications for non small
More
By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University School of Medicine Loma Linda University Children’s Hospital Assistant Professor of Public
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan, as a liver-directed treatment for adult patients with
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for adults with relapsed or refractory multiple myeloma who
More
By Dr. Anish Shah Bronx Lebanon Hospital On August 11, 2023, the U.S. Food and Drug Administration granted regular approval to niraparib and abiraterone acetate (Akeega) plus prednisone for adult patients
More
By Dr. Anish Shah Bronx Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with multiple myeloma with relapsed or
More
By Dr. Dipesh Uprety Karmanos Cancer Institute & Dr. Howard (Jack) West City of Hope What is a biomarker, and why do we test for them? A biomarker for cancer
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration granted regular approval to pralsetinib for adult patients with metastatic non-small cell lung cancer (NSCLC)
More
Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care On August 4-5, 2023, the Binaytara Foundation held the Seattle Cellular Therapy Summit. This annual conference gathers leading
More
Dr. Talha Badar of Mayo Clinic discusses the results of Quantum First, a randomized, phase III trial evaluating the efficacy of Quizartinib in treating Acute Myeloid Leukemia (AML) with FLT3-ITD mutation.
More